z-logo
open-access-imgOpen Access
Neuromuscular Pharmacodynamics of Rocuronium in Patients with Major Burns
Author(s) -
Tae Uk Han,
HyeongSeok Kim,
Jiyoung Bae,
KwangMin Kim,
J. A. Jeevendra Martyn
Publication year - 2004
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/01.ane.0000129992.07527.4b
Subject(s) - medicine , rocuronium , propofol , anesthesia , fentanyl , pharmacodynamics , adductor pollicis muscle , onset of action , neuromuscular blockade , neuromuscular transmission , neuromuscular monitoring , pharmacokinetics , surgery , ulnar nerve , elbow
Rocuronium, which has a short onset time and is free of hyperkalemic effects, could be considered for rapid-sequence induction of anesthesia in patients with burns. In this study, we assessed the neuromuscular pharmacodynamics of rocuronium in patients with major burns. Adults aged 18-59 yr who had a major burn injury (n = 56) and a control group of 44 nonburned patients were included. Rocuronium was used at 3 times (0.9 mg/kg) or 4 times (1.2 mg/kg) the 95% effective dose. Anesthesia consisted of propofol and fentanyl with nitrous oxide and oxygen. Neuromuscular block was monitored with an acceleromyograph by using train-of-four stimulation. The onset time to 95% neuromuscular block was prolonged in burned compared with nonburned patients (115 +/- 58 s versus 68 +/- 16 s for 0.9 mg/kg; 86 +/- 20 s versus 57 +/- 11 s for 1.2 mg/kg). Dose escalation shortened the onset time, prolonged the duration of action, and improved intubating conditions in burned patients. All recovery profiles were significantly shorter in burned versus nonburned groups with both doses. Resistance to the neuromuscular effects of rocuronium was partially overcome by increasing the dose. A dose up to 1.2 mg/kg provides good tracheal intubating conditions after major burns.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here